A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of D-2570 in Patients With Active Systemic Lupus Erythematosus
InventisBio Co., Ltd
120 participants
Feb 12, 2026
INTERVENTIONAL
Conditions
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy and safety of D-2570 in the treatment of active systemic lupus erythematosus.
Eligibility
Inclusion Criteria5
- The patient voluntarily participates in this study after full informed consent.
- The age is 18 years ≤ age ≤ 70 years, regardless of gender.
- Diagnosed with Systemic Lupus Erythematosus (SLE) at least ≥ 24 weeks prior to screening.
- SLEDAI-2K total score ≥ 8.
- On stable treatment for systemic lupus erythematosus at least 4 weeks prior to randomization, and should remain at a stable dose throughout the trial period.
Exclusion Criteria3
- History of infection as defined in the protocol.
- Any of the medical diseases or disorders listed in the protocol.
- Significant, uncontrolled or unstable disease in any organ.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will be assigned to one of the following groups: Group A, Group B, Group C, or the placebo control group.
D-2570 Placebo
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07311200